✦ LIBER ✦

O301 Safety of dienogest for the treatment of endometriosis: A 24-week, randomised, open-label trial versus leuprolide acetate

✍ Scribed by T. Faustmann; C. Seitz; J. Marr; C. Gerlinger; T. Strowitzki

Book ID: 117127655
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 107
Category: Article
ISSN: 0020-7292
DOI: 10.1016/s0020-7292(09)60673-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dienogest is as effective as leuprolide

Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial

✍ Strowitzki, T.; Marr, J.; Gerlinger, C.; Faustmann, T.; Seitz, C. 📂 Article 📅 2010 🏛 Oxford University Press 🌐 English ⚖ 336 KB

Sequential versus triple therapy for the

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

✍ Liou, Jyh-Ming; Chen, Chieh-Chang; Chen, Mei-Jyh; Chen, Chien-Chuan; Chang, Chi- 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 253 KB

Safety of efalizumab for the treatment o

Safety of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

Trastuzumab emtansine versus treatment o

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

✍ Krop, Ian E; Kim, Sung-Bae; González-Martín, Antonio; LoRusso, Patricia M; Ferre 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 422 KB

## Background: Patients with progressive disease after two or more her2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. we aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent dm1 linked to trastuzumab,

Dovitinib versus sorafenib for third-lin

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

✍ Motzer, Robert J; Porta, Camillo; Vogelzang, Nicholas J; Sternberg, Cora N; Szcz 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 436 KB